Investors and analysts reacted immediately to Novo's revelation. The price of Novo's common stock declined dramatically. From a closing market price of $103.44 per share on December 19, 2024, Novo's ...

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Ken Fisher is the founder and executive chairman of Fisher Asset Management, a renowned investment and financial analysis ...

An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use of “affordable” compounded weight loss drugs.

The Danish drug giant Novo Nordisk, known for its antidiabetes and weight loss drugs such as semaglutide (Ozempic or Wegovy), has been censured by the UK’s Prescription Medicines Code of Practice ...

Denmark’s Novo Nordisk (NOV: N) saw its shares rise as much as 13% to ... data analyses and commentary from our global network of life sciences reporters. Receive The Pharma Letter daily news bulletin ...

Both Novo Nordisk’s Ozempic (semaglutide ... suggesting fatty liver disease as one potential example. The potential for lifesaving benefits would justify expanding access, said Elizabeth ...

USA-based biotech IMMvention Therapeutix yesterday revealed it has entered into a strategic collaboration and license agreement with Novo Nordisk (NOV ... Receive The Pharma Letter daily news bulletin ...

The most recent trading session ended with Novo Nordisk (NVO) standing at $80.57, reflecting a -0.57% shift from the previouse trading day's closing. This change lagged the S&P 500's 0.61% gain on ...

After months of leaks and rumors, the Galaxy S25 Series is finally official! Samsung’s latest flagship devices were announced during the Winter Unpacked event on January 22, and while there weren’t ...